BARCELONA, Spain — Electronic cigarettes are as effective as the patch when it comes to helping smokers overcome the cravings of nicotine addiction, suggests the first randomized study of its kind.


The work, presented here at the European Respiratory Society (ERS) 2013 Annual Congress, and simultaneously published online in the Lancet, demonstrates that smokers using e-cigarettes and those using the patch are able to abstain from smoking in equal proportions after 6 months.


Chris Bullen, MD, director of the National Institute for Health Innovation at the University of Auckland in New Zealand, and his team compared 3 approaches to smoking cessation in 657 smokers. Participants actively trying to quit were randomly assigned to active e-cigarettes that contained 16 mg of nicotine, placebo e-cigarettes with no nicotine, or patches that contained 21 mg of nicotine.


After randomization, study participants were instructed to use the assigned method for 1 week prior to their quit date, and for 12 weeks thereafter. During the study period, all participants were offered behavioural support. The researchers assessed sustained abstinence from cigarettes 6 months after the quit date.


Overall, 5.7% of participants remained cigarette-free at 6 months. Treatment success was highest with the active e-cigarettes, followed by the patches, and lowest with the placebo e-cigarettes; however, these differences were not statistically significant.


Table. Percentage of Smokers Who Successfully Quit

Treatment Group Successful Cessation, %
E-cigarettes (n = 292) 7.3
Nicotine patches (n = 292) 5.8
Placebo e-cigarettes (n = 73) 4.1


When the researchers analysed cigarette consumption and evaluated the benefit of cutting down instead of quitting, the results were statistically significant. More participants in the active e-cigarette group than in the patch group had reduced consumption by at least half at 6 months (57% vs 41%). Differences in addiction and withdrawal scores were also significant between the 2 active-treatment groups (= .018)


There were no differences in adverse events in the 3 groups.


However, the success seen with the active e-cigarette did come with some interesting caveats. "At 6 months, more than a third of the people in that group who had quit smoking were still using the e-cigarettes," Dr. Bullen reported.


This suggests that they substituted e-cigarettes for their nicotine supply. I suppose you could argue that this is a bad thing, that you're maintaining nicotine dependence, but at least it is better than having the person continue to smoke," he said. "However, for those in the e-cigarette cohort who didn't manage to quit, about 30% now use both. This is certainly a concern, and more research is needed in the area of dual use."


If a person uses e-cigarettes to successfully quit smoking but is still using them a year later, is that a problem? Gareth Jones, MD, from the Liverpool Heart and Chest Hospital in the United Kingdom, told Medscape Medical News that a smoker who successfully quits should certainly be congratulated. "But I would be obligated to mention that I don't know what these devices will do to the lungs in the long term. As yet, there is no clear evidence on which to base an opinion. Ideally, I'd want you to quit using the e-cigarette as well, as long as it didn't mean you would go back to using real cigarettes."


The dearth of solid data is partially explained by the nature of the product. "The problem in the United Kingdom is that there is no standard e-cigarette," Dr. Jones explained. "A recent study by the World Health Organization showed that even e-cigarettes manufactured by the same company have widely variable components. There are regulations coming in the United Kingdom in 2016 that will require safety and efficacy data, but until then, we really don't know what you're inhaling."


Outgoing ERS president Francesco Blasi, MD, emphasized that more data are needed to gauge the effects of the long-term use of e-cigarettes.


"This study is an important first step in looking at the safety and efficacy of these devices," he told Medscape Medical News. "This is exactly what we want — the ERS wants more science in this regard. They've shown that in the short term, e-cigarettes are as effective as the nicotine patch, and that the safety seems good.


We are so sure you will love SMOKO, you can try a SMOKO E-Cigarette Starter Kit for FREE* (simply pay the UK Postage and Packaging) – CLICK HERE to get your E-Cigarette Starter Kit FREE!


About SMOKO Premium E-Cigarettes

SMOKO Premium Electronic Cigarettes is the UK’s leading brand of e-cigarettes.  Since starting in 2012, SMOKO has helped prevent over 85,000,000 cigarettes being smoked and have helped our customers save over £32,500,000 in extra disposable income.


SMOKO E-Cigarettes contain only the highest quality, pharmaceutical-grade ingredients that are all Made in the UK – whereas the majority of e-cigarette brands sold in grocery and convenience stores, petrol stations and on-line use Chinese-made ingredients.


SMOKO Electronic Cigarettes contain only 4 ingredients vs. the 4,000 chemicals and 50 known carcinogens found in traditional cigarettes.


SMOKO – Amazing flavour, realistic smoking sensation and quality you can trust.


The whole article is over at and written Neil Canavan 

Leave a comment

Please note, comments must be approved before they are published

Welcome to the Loyalty Points Demo Store :-)

Sign up and receive 5000 pts to test out in our Store.

Earning and redeeming SMOKO Credits

Earns you
Redeems to

Ways you can earn

  • Product Purchase
  • Refer a friend
  • Share on social media

Learn more about our program